Cancellations and suspensions

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 28/01/2020

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 28/01/2020

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 28/01/2020

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 28/01/2020

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 28/01/2020

Regulatory action due to The goods were not eligible for listing as they did not meet the requirements set out in Schedule 4 of the Therapeutic Goods Regulations., effective 16/01/2020

Regulatory action due to The Sponsor failed to comply to the notice under section 41JA within a further 10 working days from the date as specified in that notice., effective 14/01/2020

Regulatory action due to The Sponsor failed to comply to the notice under section 41JA within a further 10 working days from the date as specified in that notice., effective 14/01/2020

Regulatory action due to The Sponsor failed to comply to the notice under section 41JA within a further 10 working days from the date as specified in that notice., effective 14/01/2020

Regulatory action due to The Sponsor failed to comply to the notice under section 41JA within a further 10 working days from the date as specified in that notice., effective 14/01/2020

Regulatory action due to The Sponsor failed to comply to the notice under section 41JA within a further 10 working days from the date as specified in that notice., effective 14/01/2020

Regulatory action due to The Sponsor failed to comply to the notice under section 41JA within a further 10 working days from the date as specified in that notice., effective 14/01/2020

Regulatory action due to The device was incorrectly classified as a class I medical device. From the information available the device should be included on the ARTG at a higher classification. Therefore, the certification made by the sponsor under paragraph 41FD(c) of the Act in the application for inclusion is incorrect., effective 10/01/2020

Regulatory action due to The Secretary was satisfied that a statement made in, or in connection with, the application for listing of the goods was false or misleading in a material particular. It appeared to the Secretary that the presentation of the goods was unacceptable. As it appeared to the Secretary that the presentation of the goods was unacceptable, the certification made under s.26A(2)(c) of the Act was incorrect. The goods do not conform to a requirement relating to advertising applicable to the goods under Part 5-1 of the Act., effective 20/12/2019

Regulatory action due to Voluntary revocation at the request of the manufacturer., effective 18/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019

Regulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 16/12/2019